Nature Communications (Jul 2020)
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
- Sejin Oh,
- Jeonghun Yeom,
- Hee Jin Cho,
- Ju-Hwa Kim,
- Seon-Jin Yoon,
- Hakhyun Kim,
- Jason K. Sa,
- Shinyeong Ju,
- Hwanho Lee,
- Myung Joon Oh,
- Wonyeop Lee,
- Yumi Kwon,
- Honglan Li,
- Seunghyuk Choi,
- Jang Hee Han,
- Jong Hee Chang,
- Eunsuk Choi,
- Jayeon Kim,
- Nam-Gu Her,
- Se Hoon Kim,
- Seok-Gu Kang,
- Eunok Paek,
- Do-Hyun Nam,
- Cheolju Lee,
- Hyun Seok Kim
Affiliations
- Sejin Oh
- Severance Biomedical Science Institute, Yonsei University College of Medicine
- Jeonghun Yeom
- Center for Theragnosis, Korea Institute of Science and Technology
- Hee Jin Cho
- Institute for Refractory Cancer Research, Samsung Medical Center
- Ju-Hwa Kim
- Graduate Program for Nanomedical Science, Yonsei University
- Seon-Jin Yoon
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Hakhyun Kim
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Jason K. Sa
- Department of Biomedical Sciences, Korea University College of Medicine
- Shinyeong Ju
- Center for Theragnosis, Korea Institute of Science and Technology
- Hwanho Lee
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Myung Joon Oh
- Severance Biomedical Science Institute, Yonsei University College of Medicine
- Wonyeop Lee
- Department of Computer Science, Hanyang University
- Yumi Kwon
- Center for Theragnosis, Korea Institute of Science and Technology
- Honglan Li
- Department of Computer Science, Hanyang University
- Seunghyuk Choi
- Department of Computer Science, Hanyang University
- Jang Hee Han
- Severance Biomedical Science Institute, Yonsei University College of Medicine
- Jong Hee Chang
- Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine
- Eunsuk Choi
- Institute for Refractory Cancer Research, Samsung Medical Center
- Jayeon Kim
- Institute for Refractory Cancer Research, Samsung Medical Center
- Nam-Gu Her
- Institute for Refractory Cancer Research, Samsung Medical Center
- Se Hoon Kim
- Department of Pathology, Yonsei University College of Medicine
- Seok-Gu Kang
- Department of Medical Science, Yonsei University Graduate School
- Eunok Paek
- Department of Computer Science, Hanyang University
- Do-Hyun Nam
- Institute for Refractory Cancer Research, Samsung Medical Center
- Cheolju Lee
- Center for Theragnosis, Korea Institute of Science and Technology
- Hyun Seok Kim
- Severance Biomedical Science Institute, Yonsei University College of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-17139-y
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
The heterogeneity of IDH1/2 wild-type glioblastoma limits its prognosis and therapy. Here, the authors show a binary stratification, based on quantitative proteomic analysis of samples from patients with glioblastoma, with different prognosis and therapeutic vulnerabilities.
